This early-stage study is testing the safety and best dose of a new cell therapy called FT819. It is for adults with B-cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. Researchers are giving FT819 alone or combined with another drug…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC